Franklin Resources Inc Allogene Therapeutics, Inc. Transaction History

Franklin Resources Inc

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	BUY	$3.17 - $5.96 $4,048 - $7,610	1,277 Added 5.42%	24,853 $78,000
Q2 2023 Aug 11, 2023	BUY	$4.53 - $6.74 $106,799 - $158,902	23,576 New	23,576 $117,000
Q1 2020 May 13, 2020	SELL	$18.22 - $28.25 $11.1 Million - $17.3 Million	-610,697 Closed	0 $0
Q4 2019 Feb 12, 2020	SELL	$24.82 - $31.4 $4.42 Million - $5.59 Million	-178,082 Reduced 22.58%	610,697 $15.9 Million
Q2 2019 Aug 14, 2019	SELL	$25.56 - $31.09 $5,112 - $6,218	-200 Reduced 0.03%	788,779 $21.2 Million
Q1 2019 May 14, 2019	BUY	$24.82 - $32.54 $7.19 Million - $9.43 Million	289,797 Added 58.05%	788,979 $22.6 Million
Q4 2018 Feb 12, 2019	BUY	$22.5 - $33.3 $11.2 Million - $16.6 Million	499,182 New	499,182 $13.4 Million

163

134M

59.4K

113K

Ticker ALLO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 143,807,008
Market Cap $240M
Description
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult p...

Get notified when there are updates to the investment portfolio of Franklin Resources Inc, based on Form 13F filings with the SEC.

Stay updated on Franklin Resources Inc with notifications on news.